cefradine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 576 | 38821-53-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semi-synthetic cephalosporin antibiotic.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
| 2 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 26 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 86 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 190.89 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 94 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.21 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.95 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.85 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 19, 1974 | FDA | APOTHECON |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal monitoring abnormal | 63.25 | 59.87 | 8 | 442 | 186 | 79743752 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DB09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute otitis media | indication | 3110003 | |
| Prostatitis | indication | 9713002 | DOID:14654 |
| Haemophilus Influenzae Acute Otitis Media | indication | 19021002 | |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Staphylococcal pneumonia | indication | 22754005 | |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Streptococcal tonsillitis | indication | 41582007 | |
| Lower respiratory tract infection | indication | 50417007 | |
| Upper respiratory infection | indication | 54150009 | |
| Klebsiella cystitis | indication | 60867007 | |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Tonsillitis | indication | 90176007 | DOID:10456 |
| Infection of bone | indication | 111253001 | |
| Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
| Pneumonia | indication | 233604007 | DOID:552 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Infective otitis media | indication | 312218008 | |
| Infectious disorder of joint | indication | 363162000 | |
| Pharyngitis | indication | 405737000 | DOID:2275 |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Staphylococcus Acute Otitis Media | indication | 703469002 | |
| Enterococcus Urinary Tract Infection | indication | ||
| Klebsiella Prostatitis | indication | ||
| Prevention of Perioperative Infection | indication | ||
| Proteus Prostatitis | indication | ||
| Enterococcus Prostatitis | indication | ||
| Acute nephropathy | contraindication | 58574008 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.77 | acidic |
| pKa2 | 7.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Matrix metalloproteinase-9 | Enzyme | IC50 | 5.40 | WOMBAT-PK | |||||
| Somatostatin receptor type 4 | GPCR | IC50 | 4.30 | WOMBAT-PK | |||||
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4017745 | VUID |
| N0000146111 | NUI |
| D00264 | KEGG_DRUG |
| 2239 | RXNORM |
| C0007738 | UMLSCUI |
| CHEBI:3547 | CHEBI |
| CHEMBL1604 | ChEMBL_ID |
| DB01333 | DRUGBANK_ID |
| 4830 | IUPHAR_LIGAND_ID |
| 38103 | PUBCHEM_CID |
| 3082 | MMSL |
| 4397 | MMSL |
| d00053 | MMSL |
| 002718 | NDDF |
| 16791000 | SNOMEDCT_US |
| 387091007 | SNOMEDCT_US |
| D002515 | MESH_DESCRIPTOR_UI |
| 4017745 | VANDF |
| F1BC02I72W | UNII |
Pharmaceutical products:
None